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Abstract

DNP FINAL REPORT: BUILDING A COMPREHENSIVE GUIDELINE TO IMPROVE THE
TREATMENT OF INFANTS WITH NEONATAL ABSTINENCE SYNDROME: ADDING
NON-PHARMACOLOGICAL INTERVENTIONS TO A MORPHINE PROTOCOL
Cyndi B. Kelley, MSN, RNC-LRN
DNP Project Team Chair: Ellen Fineout-Overholt, PhD, RN, FNAP, FAAN
The University of Texas at Tyler
May 2020
Background: The incidence of Neonatal Abstinence Syndrome (NAS) has increased nationally;
however, only 55% of NICUs indicated having a written NAS treatment plan as recommended
by the American Association of Pediatrics. Current practice included symptom management via
morphine only; however, non-pharmacological interventions were not routinely delivered.
Purpose: The purpose of this project was to standardize and improve the care provided to
patients with NAS.
Methods: A systematic search was conducted using keywords and subject headings from the
PICOT question. Retrieved synthesized evidence suggested that adding breastfeeding and
rooming-in as first line treatment options reduced the length of hospital stay and medication
treatment. An interprofessional council developed and implemented a comprehensive treatment
guideline featuring education on addiction, trauma informed care, evidence-based NAS treatment
options, and Finnegan scoring.
Results: Post-education knowledge assessment scores were 100 percent. Hospital length of stay
was reduced from 27 (2017) to 17 days (2019) and length of morphine treatment was reduced
from 34 (2017) to 20 days (2019). Associated hospital all NAS cases costs dropped from
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$499,709 pre-intervention to $192,573 post-intervention. The guideline is now the standard plan
of care to ensure that all NAS patients receive best practice.
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Chapter 1: Development of the Leadership Question and Problem Identification (EBP
Process Steps, 0, 1, & 2)
Background and Significance
In December 2016, a young couple welcomed their newborn daughter to the world. She
was a beautiful baby with dark hair and a stunning smile. Unfortunately, Gracelynn tested
positive for opiates because of her mother’s heroin use during pregnancy. Within forty hours of
birth, Gracelynn experienced blood sugar instability, intermittent high pitch cry, tremors, nasal
congestion, and increased muscle tone. During this time, Gracelynn received controlled opioid
doses to manage painful withdrawal symptoms; she was experiencing a condition called
Neonatal Abstinence Syndrome (NAS). When they learned of Gracelyn’s condition, Child
Protective Services (CPS) removed custody of Gracelynn from her mother and father and
restricted parental visitation to supervised visits, only in the presence of a CPS caseworker.
Gracelynn’s grandmother could visit without restrictions. Gracelynn spent many days alone in
her hospital room. The lack of interactions, including holding, eye contact, talking, and touch,
increased her irritability, leading to delays in weaning or escalations in medication dosage.
Ultimately, Gracelynn’s hospitalization lasted a total of 63 days, well beyond the average 16-day
length of stay (LOS) for NAS (Patrick et al., 2012).
The Center for Behavioral Health Statistics and Quality’s 2014 national survey on drug
use and health (2015) indicated 44.5% of females, 12 years old or older, reported illicit drug use
in their lifetime. The incidence of non-medical use of opioid pain relievers is highest in women
18 to 25 years old. The current opioid crisis raises significant concerns in that as substance use
issues in women of childbearing age continue to multiply, the number of NAS cases will follow.
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Drug overdoses come in second to car accidents as the number two cause of injury/death in the
US (Leonard, 2016; Chopra & Marasa, 2017). 21.5 million Americans suffer from substance use
disorders, including 1.9 million using prescribed opioids and nearly 600,000 using heroin
(Centers for Disease Control and Prevention, 2016; Chopra & Marasa, 2017). Heroin-related
deaths tripled between 2010 and 2013, while opioid-related deaths among women increased by
400% between 1999 and 2010 (Chopra & Marasa, 2017). Over the past decade, the use of
opiates during pregnancy has significantly increased and has become a compelling public health
concern (Stover & Davis, 2015). Prescription opioid use in pregnancy positively correlates with
neonatal complications; opiate use can lead to intrauterine growth restriction, placental
abruption, preterm birth, oligohydramnios, stillbirth, and maternal death. Adverse infant
neurodevelopmental outcomes also have been shown to result from maternal drug use during
pregnancy (Stover & Davis, 2015).
NAS is a constellation of behavioral and physiological signs and symptoms resulting
from exposure in utero to maternal drug use of opioids, stimulants, depressants, cigarettes,
serotonin reuptake inhibitors (SSRI), or any combination thereof (MacMullen, Dulski, &
Blobaum, 2014: Chopra & Marasa, 2017). Fifty-five to 94% of infants exposed to drugs in utero
will develop NAS (Minnesota Hospital Association, 2013). Most NAS symptoms manifest in
the central and autonomic nervous systems as well as the gastrointestinal tract (Jensen, 2014).
Symptoms can include, but are not limited to, hyperirritability, tachypnea, poor sleep or feeding
patterns, and tremors (MacMullen, Dulski, & Blobaum, 2014). The onset of symptoms and
intensity vary between babies; symptom onset ranges from three to seventy-two hours. Duration
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for opioid withdrawal symptoms can last from 10-30 days; duration is dependent on the type of
drug, dosage, and frequency the infant is exposed to in utero.
Symptoms are managed medically with medications including morphine, methadone, and
Buprenorphine. To determine if the infant requires pharmacological intervention, healthcare
providers use scoring tools such as Lipsitz, the Finnegan Neonatal Scoring Tool (FNAST), and
the newest option, Eat, Sleep, and Console. The FNAST tool quantifies the most common
symptoms presented by the infant. The FNAST contains 21 clinically significant items in three
categories; each FNAST category is weighted differently in the total score. The categories
include central nervous system disturbances, metabolic, vasomotor, and respiratory disturbances,
and gastrointestinal disturbances. The pharmacologic treatment starts following three scores at
or above eight or two scores at or above 12 on consecutive assessments. Once symptom control
has been achieved (as indicated by the FNAST scores), the weaning process starts.
External Evidence
Between 2009 and 2012, the incidence of NAS increased nationally from 3.4 to 5.8 per
1,000 hospital births, totaling 21,732 infants with the diagnosis in the U.S with $316 billion
spent annually. The incidence rate for Texas increased by 60%, reaching 2.6 per 1000 births
leading to $29 million in costs (Texas Department of State Health Services, 2017). While not the
highest national statistic, it is a rapidly growing concern across the state (Patrick, Davis, Lehman,
& Cooper, 2015). Bexar, Dallas, Harris, Tarrant, and Nueces counties had the highest number of
NAS cases in 2015 (Texas Department of State Health Services, 2017). Dallas County saw two
in every 1000 births results in the development of NAS and spent millions annually on
hospitalization of this patient population. In 2006, 55% of Neonatal Intensive Care Units
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(NICU) indicated having a written plan for NAS treatment (Patrick et al., 2016). The American
Academy of Pediatrics (AAP) published a clinical report recommending, “…each nursery should
develop and adhere to a standardized policy for the evaluation and comprehensive treatment of
infants at risk for or showing signs of withdrawal” (Hudak & Tan, 2012, pp. e554). Patrick et al.
(2016) indicated standardization of patient care and hospital policies would improve overall
patient outcomes. Despite this revelation, there is no nationally established standardized
treatment guideline available to date for the care of this patient population.
Internal Evidence
Much like the growing national and state incidence rates, in 2017, Texas Health
Presbyterian Hospital of Dallas (THD) experienced a 55% increase in infants with NAS.
Currently, NAS patient treatment at THD includes symptom management via morphine. A
morphine protocol has been in place since 2014, yet not consistently prescribed or followed by
all physicians. The lack of a standardized adherence to the current protocol has led to morphine
dosage weaning and escalation fluctuations, thereby increasing the length of time for the infant's
treatment. Additionally, the FNAST tool is inconsistently used due to isolated staff training and
an overall lack of knowledge pertaining to the 21 clinical definitions, leading to a great deal of
subjectivity. Staff ensure babies with NAS receive minimal stimulation (decreased lighting and
noise and clustered care), which results in a reduction in parental participation. Like other
NICU’s across the county, THD does not have a comprehensive guideline for the treatment of
patients with NAS.
Development of the Clinical Question and Problem
Considering the increase in the NAS patient population, lack of a comprehensive
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guideline, extended length of stay and treatment, increased costs, and recommendations from
professional associations, a comprehensive NAS treatment guideline is warranted. A guideline
inclusive of nonpharmacologic interventions and pharmacological treatment, used consistently,
could improve patient outcomes. Therefore, the question arises, in neonates with Neonatal
Abstinence Syndrome (P), how does adding non-pharmacologic therapies to the current
medication protocol (I) compared to current medication protocol alone (C) affect the length of
stay (O) and duration of treatment (O) within one quarter (T)?
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Chapter 2: Systematic Search, Evidence Synthesis & Project Models (EBP Process Steps 1,
2, 3, & 4)
Systematic Search
A systematic search of three online databases was completed using the PICOT question
as a guide, including, Cumulative Index of Nursing and Allied Health Literature (CINAHL),
Cochrane Library, and PubMed. Keywords or subject headings searched included, neonatal
abstinence syndrome, length of stay, length of treatment, alternative therapies, nonpharmacological treatment, pharmacological treatment, and medication management. Since
many versions of the terms pharmacological and therapies exist, the truncated search terms
pharm* treatment, non-pharm* treatment, and alternative therap* also were used across all
databases.
The initial yield from CINAHL was 149, 266 potential articles. Terms were combined
using Boolean operators to narrow the yield to 13,760 articles. The inclusion criteria of English
language, full text, all infant sample, academic journals, and peer-reviewed were then added and
resulted in a reduced total yield of 123 relevant articles. Evaluation for relevancy resulted in a
final total of 33 relevant articles (Appendix A, Figure A1).
The Cochrane Library database was searched using key terms as listed above (and
truncation symbol asterisk). The search resulted in a yield of 335,763. Combining key terms
with the Boolean operator AND (to combine like terms) and OR (to consolidate like terms)
resulted in a yield of 44,200 The inclusion criteria included review only, to isolate systematic
review articles, while studies were included for non-relevance and duplicate reviews. The final
yield was zero (Appendix A, Figure A1), indicating there were no Cochrane systematic reviews.
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The final database searched was PubMed using the same key terms as mentioned above.
The initial yield was 4,635,907. Pairing the keywords with Boolean operators OR and AND
resulted in a yield of 407,628. Further narrowing the results, the inclusion criteria of full text;
humans; English language; Newborn: birth-1 month was applied to bring the final yield to 97
(Appendix A, Figure A1).
A final hand search was performed of the 97 retained articles, yielding an additional 16
articles, for a final yield of 113 potential articles to put forward for critical appraisal. After
review of title and abstract, a total of 8 articles were retained for the critical appraisal.
Critical Appraisal
Melnyk, Fineout-Overholt, Stillwell, and Williamson (2010) indicated, “Step 3: Critically
appraise the evidence” follows the systematic search. When comparing the research against the
hierarchy of evidence as indicated by Melnyk, Fineout-Overholt, Stillwell, and Williamson
(2010), the eight articles were 2-Level I, 5-Level IV, and 1-Level V.
Rapid Critical Appraisal
Eight articles were evaluated utilizing a rapid critical appraisal (RCA), which is the
process of systematically assessing the quality, outcomes, and applicability of the evidence. For
identifying keeper studies, specific study design rapid critical checklists (RCAC) helped evaluate
the literature. For example, an RCAC of descriptive studies is different from the RCAC for
qualitative evidence. Additionally, a General Appraisal Overview (GAO) enabled a proper
assessment of each study’s purpose, subjects, sampling techniques, and major variables, among
other aspects of the studies. The result of rapid critical appraisal with GAO & RCA yielded six
keeper studies (Appendix B, Table B1).
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Evaluation
For ease of comparison study data, an evaluation table was developed (Appendix B,
Table B2). Aspects of the study were compared for differences and commonalities. Across
studies, independent variables included one or more of the following: breastfeeding, rooming-in,
specialized bed, positioning, and non-insertion acupuncture. Dependent variables included
hospital length of stay and length of medication treatment, but not all variables were evaluated
for their impact on the dependent variables (Appendix B, Table B3). Two studies were
systematic reviews (Bagley et al., 2014; Edwards et al., 2016), three were retrospective cohort
studies based in a single facility (McKnight et al., 2014; Short et al., 2016; Well-Strand et al.,
2013), and the final article was a meta synthesis (Boucher, 2017).
Studies in Bagley et al. (2014) and Edwards et al. (2014) reviews supported that BF had
an impact on LOS and LOT (Appendix B, Tables B4 & B5). Edwards and Brown (2016) found
that breastfed infants increased symptom management, reduced need for medication treatment,
delayed onset of symptoms, and a reduced length of treatment. Additionally, breastfed infants
had a shorter period of stay requiring only 12.5 days compared to 18.5 days, a profound
difference from the current LOS within the SCN and justification for considering breastfeeding
as supportive therapy. The supportive nature of breastfeeding is further corroborated by Short,
Gannon, and Abatemarco (2016) who conducted a retrospective cohort study appraising
breastfeeding and its impact on the length of stay. The median length of stay for nonbreastfeeding infants was twelve days, two days longer than breastfed infants. Breastfeeding and
length of stay have an inverse relationship, supporting previous results from other studies.
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Like Bagley, Wachman, Holland, and Brogly (2014), findings by Edwards and Brown
(2016) indicate infants who roomed-in had less severe symptoms of NAS, required less
pharmacologic treatment, and a shorter length of stay. Rooming-in enabled the mother and
infant to be together, improving bonding, and decreased the admissions to the NICU; fewer
admissions to the NICU ultimately reduces the hospital’s financial burden. Furthermore,
rooming-in was shown to aid in the reduction of length of stay and duration of treatment and was
also statistically significant, according to Hunseler (2013) and Abrahams (2007). Boucher
(2017) reviewed the literature to evaluate rooming-in as a nonpharmacological therapy in the
treatment of NAS symptoms and the impact on the length of stay. The research examined led the
author to believe that rooming-in may lead to a reduction in the length of the hospital. The
duration of treatment dropped by five days in the infants who roomed in with their mother. The
researchers suggest the developmental benefits of rooming-in outweigh the risks.
Bagley, Wachman, Holland, and Brogly (2014) suggest a potential supportive and synergistic
relationship between rooming-in and breastfeeding, who also evaluated the impact of rooming-in
on NAS management. This relationship is supported by McKnight, Coo, Davies, Holmes,
Newman, Newton, and Dow (2015), who analyzed rooming-in and its impact on NAS symptom
management. Results indicate infants who roomed in required fewer days of pharmacologic
treatment and reduced hospitalization. While there was a higher proportion of breastfeeding
infants in the rooming-in group, it was not a significant difference. Rooming-in supported
symptom management, independent of breastfeeding. Rooming-in and breastfeeding may
significantly improve outcomes if used in conjunction. Edwards and Brown (2016) rooming-in
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exploration included many infants who breastfed, combining two non-pharmacological
interventions.
Bagley, Wachman, Holland, and Brogly (2014) evaluated the use of a specialized bed in
the management of NAS symptoms. Using a rocking bed (with replicated intrauterine sounds)
did not show a significant difference in withdrawal scores and led to sleep disturbance issues due
to the constant noise; continuous noise can overstimulate an infant with NAS. Non-oscillating
water beds used with this patient population led to less medication for treating symptoms,
although more research is required. Specialized beds lack a determination to reduce the length of
hospital stay. Edwards and Brown (2016) found the use of waterbeds with breastfeeding infants
supported less severe NAS symptoms and were less likely to require treatment with opiates
resulting in a reduced LOT. In comparison, a study examining the use of rocking beds found this
intervention to be too stimulating to this patient population and therefore not a recommended
treatment.
Bagley, Wachman, Holland, and Brogly (2014) found in conjunction with the beds,
placing the patient in a prone position positively supported symptom management. While the
results are positive for the use of positioning as an intervention, more studies are required to
support the ongoing use and addition of this tactic. Edwards and Brown (2016) suggest the use
of positioning in the NAS population is a new concept, but one which requires consideration.
Prone positioning appears to alleviate NAS symptoms and the infants placed in the prone
position experienced lower withdrawal scores.
Boucher (2017) reviewed the literature to evaluate acupuncture, noted as non-insertive
acupuncture (NIA), as a potential treatment for NAS symptoms as well as NIA’s impact on
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length of stay. The authors suggest infants had better feeding sessions and their caloric intake
was improved following NIA. Sleep in this patient population was also improved just after NIA
treatment was performed. Agitated or infants who were hard to console appeared to have the
most improved outcomes with the use of NIA treatment. Edwards and Brown (2016) found
acupuncture to be a supportive therapy for infants with NAS. Infants appeared to have improved
sleep and feeding following treatment with NIA, but the researchers did not link NIA with LOS
or LOT. Acupuncture is a controversial area and one that requires more research to support its
acceptance.
Synthesis
From the evaluation table, interventions were extrapolated from each article and
compared for their impact on LOS and LOT (Appendix B, Table B3). Synthesis of the body of
evidence revealed that the inclusion of breastfeeding, as a non-pharmacologic intervention,
resulted in a statistically significant reduction in length of treatment and length of stay for NAS
patients; specifically, hospitalizations were 3-19 days shorter in infants who breastfed. From the
10 studies reviewed by Bagley et al. (2014); Edwards et al. (2016) six supported that BF reduced
infant LOS and LOT (Appendix B, Tables B4 & B5).
Rooming-in was shown to enable the mother and infant to be together, improve bonding,
and decrease the admissions to the NICU. Rooming-in was shown to aid in reducing the length
of hospitalization and medication treatment. There were not enough studies to support that
specialized beds, prone positioning or acupuncture had a reliable impact on length of hospital
stay or symptom management.
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Recommendations
Based on the evidence, non-pharmacological interventions of breastfeeding and roomingin should be routine care for infants suffering with NAS symptoms. These non-pharmacological
interventions should be included into the care of the baby through the initial phase of withdrawal.
When the infant’s symptoms can no longer be managed with non-pharmacological interventions
alone, the Morphine protocol should then be added. Given this contrasts with current practice,
the recommendation for implementing these interventions is to develop and implement a
comprehensive treatment guideline for the care of infants with NAS indicating initial treatment
with non-pharmacological interventions of breastfeeding and rooming in and followed by the
established morphine protocol.
Evidence-Based Practice Model
To simplify the process of implementing a new evidence-based practice into the hospital
setting, the Johns Hopkins Nursing Evidence-Based Practice Model (JHMEBP) (Appendix C,
Figure C2) was adopted into this project. The “PET” process includes the development of a
practice or clinical question, the systematic search of the evidence, and then translation of the
evidence into practice (Brooks-Staub, 2005). According to the Daemen Library (2018), the goal
of the model is to “ensure that the latest research findings and best practices are quickly and
appropriately incorporated into patient care” (pp. 1). Once the clinical question was established,
a standardized search strategy was developed and used to search the most current and applicable
evidence. The evidence is thoroughly evaluated and synthesized to answer the clinical question
for intervention development. Once the intervention is developed, the project plan is initiated,
and a change model is selected to begin the process of translating the science into practice.
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Lewin’s Change Theory
Change is an inevitable part of healthcare. To facilitate change related to this project,
Kurt Lewin’s Change Model (Appendix C, Figure C3) will set the foundation for careful
consideration of how this project would lead to practice change. Lewin’s Change Model outlines
three steps to change including unfreezing, changing, and refreezing. During “unfreezing”, it is
important to find ways to help others let go of old habits. This can be done by increasing driving
forces away from current patterns, decreasing the restraining forces causing negative movement
from neutral, or a combination of the two (Nursing Theory, 2016). Movement during the
“change” stage includes process changes in thoughts, feelings, behaviors, or a change in all three
that leads to a new sense of liberation. “Refreezing” is when the change is now the new status
quo. Using this model, change would be planned, systematic, and thoughtful resulting in
outcome success.
In the first stage, staff and physicians would be made aware of the need for change
through case studies, internal data, and current evidentiary recommendations (unfreezing).
During this time, a new comprehensive and evidence-based guideline would be developed in
partnership with staff and physicians who volunteers to participate in the project. Moving into
the change stage, those impacted by the new guideline would receive education and training on
the use of the guideline prior to implementation. Practice expectations would be established and
then the guideline would be implemented. The refreezing stage would include data collection,
celebration of successes, and review of outliers.
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Chapter 3: Project Design and Methodology (EBP Process Steps 3-4)
Project Design & Methodology
To bring the evidence-based recommendation to fruition required planning included the
development of a logic model, a timeline, and a Gantt chart all grounded in the evidence-based
practice model and the change model previously mentioned. Before the EBP project was
launched, to ensure the full support of the project, an executive summary (Appendix D) was
submitted to the interim Chief Nursing Officer (CNO) who then provided approval for
implementing the project within the facility (Appendix E, Form E1). Furthermore, two industry
mentors signed on in support (Appendix E, Form E2 & E3). Lastly, due to organizational
requirements, I worked with the entity nurse scientist in preparation of Institutional Review
Board (IRB) approval. A Quality Improvement Evidence-Based Practice Assessment form was
completed and submitted to the IRB for project determination (Appendix F, Ethics Review Form
F1 & F2), and IRB support was secured (Appendix F, Ethics Review Form F3).
Operationalization Plan
During the beginning of this project, it was important for every unit to have input,
therefore an interdisciplinary team was created, called the NAS Council. This council was
comprised of one individual from each of the women and infant units who would interact or
provide care for the target patient populations (women with substance use issues and their
newborn baby). From this team, the logic model, timeline, and Gantt chart were completed
including the required milestones, tasks to achieve each milestone, responsible parties, and all
deadlines associated.
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Timeline and Gantt chart
A timeline was created using the goals established from the logic model (Appendix G,
Table G1). Milestones were fixed as checkpoints on the timeline. In evaluating the milestone,
tasks were laid out for each checkpoint. The timeline enabled the project to stay on track with
forward momentum. To further visualize the timeline and associated milestones/tasks, a Gantt
chart was developed (Appendix G, Figure G2). A Gantt chart is a visual tool and schedule
representing the milestones of the project with assigned dates. Under those milestones, the
individual associated tasks were highlighted, each with a date of completion assigned.
Logic model
A Logic Model was created to define the inputs (resources, contributions, and people),
outputs (activities, services, and events), and outcomes (results or changes related to the projects
interventions) (Appendix G, Figure G1). The logic model helped to create an overview of this
project by identifying the short- and long-term goals, including that the NAS guideline was
finalized and approved by medical director, and the expected outcomes of reduced length of
hospital stay and length of medication treatment. From these goals, we evaluated “inputs”,
which are the things that will be invested in this project such as finances, staffing, technology,
and equipment. Additionally, we investigated the outputs to identify the activities currently
being practiced and pertaining to the project as well as the people those activities are aimed. The
logic model helped to isolate the information known about the project and identify
uncontrollable external factors may impact the project. Through this model, we were able to
pinpoint what is readily available and what is missing so the gaps can be filled. As the project
developed, the logic model was adjusted to include new information and details.

15

Project Progress
Following several initial meetings with the NAS Council, the first and most important
task identified by the council members was to draft, edit, and finalize a comprehensive treatment
guideline that includes the current morphine protocol and the evidence-based nonpharmacological interventions as outlined in the body of evidence. The team met with the
medical director and began the first draft of the guideline. The guideline was shared with one of
the industry mentors for additional input as he was the content expert. This process took
approximately 6 months to complete. The final draft of the NAS guideline was submitted
through the policy committee for approval and upload to the internal policy database (Appendix
H).
Through the many meetings regarding the guideline, the NAS council representatives
expressed concerns of staff and physician’s lack of baseline knowledge as evidenced by the lack
of consistency in following the weaning and escalation steps outlined in the current morphine
protocol. An additional moment of concerned sparked from an obstetric department meeting in
which opiates during pregnancy was a topic of discussion. During the meeting, NAS was
mentioned. One physician asked, “What is NAS?” This situation was discussed during an NAS
Council meeting. The Council recommended developing an education module to prepare staff
and physicians for the implementation of the guideline. Further discussion led to an additional
recommendation of developing and adding education on the topics of addiction, trauma-informed
care, NAS interventions, Finnegan scoring, in addition to the new treatment guideline. This
would establish a solid foundation to elevate the staff and physician’s knowledge and
understanding of these topics. The timeline and Gantt chart was updated with the new milestone
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and tasks including the following: the council developed sub-committees and each group would
take a topic and develop an evidence-based module for consideration. The NAS Council met an
additional four times to edit and finalize the modules of which they submitted to the following
for approval:


Neonatology Department – medical director and content expert



Pediatric Department – medical director and one additional physician representative



Women and Infant’s Leadership Team – managers of impacted departments and
director



Education Department –women’s and infant’s educators

EBP Model
From my experience with Gracelynn, I use the Johns Hopkins Nursing Process Model for
evidence-based implementation to guide this project from start to finish. I first formulated a
background question. I used the question to extract key terms to search online the online
databases of CINAHL, PubMed, and Cochrane library for the most current and applicable
evidence. I synthesized the evidence to answer the clinical question and then translate the
evidence into practice.
Change Model
To facilitate a planned change, I used Lewin’s Change Theory, to break down the project
into three stages including “unfreezing” old habits, implementing the “change” we want to see,
and “refreezing” the new habit as the best practice. In the “unfreeze” phase, we educated all
stakeholders through case studies and an education package. When the “change” was planned
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for rollout, we implemented the guideline, monitored for compliance, redirected those who fell
out of compliance back to the guideline and reminded them of why we were making this change.
As we entered the “refreeze” phase, we collected data and reported out our project in several
different settings. We celebrated our successes and planned growth and development of the
project.
Final budget
The estimated data from the logic model enabled me to draft an email, to the director and
interim CNO, that would highlight the financial impact of the project would make on the
organization. Initial estimates included costs associated with items such as projectors and
computers and since the unit already owns these items, they become budget neutral. The final
budget consisted of time spent for staff and physicians to complete the education ($4000) prior to
the implementation of the guideline as well as the time spent by the project’s members to
develop the education modules and the guideline ($5500). With the understanding the only
financial requirement would come in the form of time spent reviewing the education modules,
the director, and interim CNO gave the greenlight to move forward with the project’s
implementation.
Data Collection Plan
The following were deemed as process indicators and outcome measures to be collected
in relation to this project:
Process indicators
•

Percent of providers education/completed modules
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•

Pre and post-test reliability scores

Outcome measures
•

Length of hospital stay

•

Number of days of pharmaceutical treatment outcome

•

Pre and post intervention total hospital cost by NAS diagnosis by year

Pre - Post knowledge transfer assessment surveys evaluate the effectiveness of staff and
physician’s education about providing care to infants with NAS. It was also important to track
the number of staff and physicians who completed the education modules to ensure the message
reached as close to 100% of the target audience as possible. These data points would be
collected direct from the SharePoint platform in which the education modules were housed and
by the assigned project members only. No identifying information was collected from the staff
or physicians other than job role.
Outcome measures would determine the efficacy of the intervention and included the
length of hospital stay, length of morphine treatment and will demonstrate the project’s success
or failure. The outcomes data collection plan consisted of two parts: (1) Pre project and post
project data obtained by submitting a request to finance for a list of infants (account number,
medical record number, date of birth, date of discharge, ICD9/10 diagnosis code, total cost of
hospital stay) with a diagnosis related to drug withdraw and their total LOS, and (2) Pre project
and post project data obtained by submitting a report request to pharmacy (including the above
report) detailing the patients from the list who were treated with morphine (date morphine
initiated, date morphine discontinued, and the total duration of morphine treatment). Data
stewardship was implemented to ensure all private patient information was kept secure,
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including all data collected were deidentified, assessed and aggregated prior to dissemination.
Ownership of the data remained secure on a password locked spreadsheet with limited access to
those involved in the data collection process. Access of data was limited to NAS council
members in charge of data collection.
Data Analysis Plan
The final dataset was evaluated for any missing data and cases were removed with any
missing data points. Absolute differences for knowledge transfer scores, LOS, LOT were
calculated by case for the various time periods within the project. Mean differences were
reported for by case outcomes to demonstrate success or failure of the education or intervention
in this setting. Absolute differences for number of providers educated and total costs by
diagnosis were calculated for the various time periods within the project.
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Chapter 4: Project Implementation, Outcomes, Impact, and Results (EBP Process Steps 4
& 5)
Process Indicators/Milestones
The first milestone included developing, reviewing, finalizing, and submitting the
evidence-based treatment guideline through the policy committee (Appendix H). Once this
process was complete, the guideline was uploaded into the hospital system’s online policy
database. The second milestone was the completion and launching of the evidence-based
education modules including the accompanying pre and posttests. The education module would
be open to participants for 6 weeks. Unit leaders were asked to add information about
participation to daily huddles, weekly emails, and individual communications, which kept the
project fresh on the participant’s minds. Once the 6 week period was complete, data was
collected from the SharePoint platform, requested from finance, and requested from pharmacy.
Lessons Learned
One of the most important lessons learned was the process for requesting a specific
platform that would meet the needs of the project. In the implementing hospital system, there are
limited number of available platforms. During this project, I learned there is an established
method of requesting platforms. The project lead is required to submit a request to a centralized
network of hospital system educators. That request is then taken to the education council to
review and investigate options. If a platform is available, the council will notify the requestor
and obtain the appropriate access for use.

21

Barriers
One barrier to achieving outcomes for the project was the platform used to house the
education intervention modules. The SharePoint platform enabled the staff and physicians to
complete a pre-test (three questions), review the education material, and a post-test (same three
questions). Several staff reported an inability to log onto the SharePoint. Additionally,
navigation of the education material was not ideal for staff, who had to use the back button to
take them to the home page to continue to the next phase of the education package versus a
smooth logical transition to the next module. SharePoint was chosen because of its ability to
provide the pre/post-testing of staff completing the educational modules. Furthermore, since
physicians are not internal employees of the organization with a hospital email address, they
could not be added as users on the SharePoint site, which hindered the educational intervention
delivery
Because of the platform challenges, 52% of available staff and physicians were not able
to log on and successfully complete the education package. Additionally, only one physician
completed all the modules, with one other partially completing. Due to the lack of physician
participation, inconsistency in practice is still an issue in need of resolution.
Solutions
As we ended this project, I met with leaders within the entity and discussed the desire to
relaunch the education module in order to reach the participants we missed during our first run.
It was decided a new platform would be necessary. I worked with the education department to
find a platform that will meet the needs of the project so that physicians can participate in the
education and evaluation. The aim was to have 100% completion by all audience members by
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December 2020. A request was submitted, and the education council reviewed the request
several times. Unfortunately, there is not a platform that will be easy for staff and physicians to
access that will allow us to collect pre and post knowledge transfer assessments. This put the
NAS council in a position where we had to decide to either reuse the SharePoint site or go out of
the system and find a platform unsupported by the hospital system. To date, this is still being
investigated by the education council members in hopes of finding a platform to meet our needs.
Project Results
As mentioned previously, the following were process indicators for this project: percent
of provider’s education/completed modules and pre and post-test reliability scores. The module
was launched and given a six-week deadline. Following the deployment of the education
module, of the 120 available staff and physicians who were able to access the platform where the
modules were housed, 48% were able to complete the entire education package (Appendix I,
Table I6). Pretest results included the following: trauma-informed care (94%), addiction (90%),
Finnegan Scoring (57%), NAS interventions (72%), and the new NAS treatment guideline
(93%). For each of the five education components, participating staff and physicians achieved a
100% score on the posttest after reviewing the education presentation, which indicates the
education provided was successful (Appendix I, Figure I3).
Once the education module deadline was met, the NAS guideline was officially
implemented into practice. Outcome measures collected included the length of hospital stay,
length of pharmaceutical treatment (morphine), and total hospital costs NAS diagnosis code and
by year. Data was collected for years 2014, 2015, and 2016 to establish baseline data. In 2017,
there were 23 cases of NAS who stayed an average 31 in the hospital and received an average of
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34 days of morphine treatment. In 2019, there were 19 cases of NAS who stayed an average of
17 days and received an average of 20 days of morphine treatment (Appendix I, Figure I4).
These results indicate the implementation of an evidence-based treatment guideline paired with a
comprehensive education package were successful in reducing the length of stay by 14 days and
the length of morphine treatment by 14 days. This resulted in a savings of $307,136 in hospital
costs (Appendix I, Figure I5).
Data Collection
Outcome measures collected from a requested finance report included the number of
NAS cases, length of hospital stay, and the total cost of hospitalization by diagnosis and year.
Baseline data was collected for the years of 2014 through 2017 and post-intervention data was
collected for years 2018, and 2019. The finance report also included individual patient medical
record number of which a pharmacy representative could use to extrapolate the start and end date
of morphine treatment. Raw data was collected from the SharePoint site including total number
of staff completing the entire education module, total number of staff partially completing the
education module, pretest scores by job role for each education section, and posttest scores by
job role for each education section.
Data Analysis
Using the finance report, the number of NAS cases were totaled and reported by year.
The total length of stay was collected from each NAS case and then averaged and reported by
year. Associated hospital costs for each NAS case were totaled and reported by year. The
finance report was submitted to the NAS council pharmacy representative. She used the account
numbers to conduct a manual extraction of data including the date of morphine initiation and the
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date of morphine discontinuation. From this, each case had a total length of stay. The average
length of hospital stay was calculated and reported by year.
Outcome Measures
Of the 120 available staff and physicians who were noted as potential participants, 118
completed at least one of the 16 components of the education module. Fifty-eight completed the
entire module, which translates to 48% of staff completed 100% of the module. We looked at
the pre-test scores and knew the Finnegan scoring module would be tough as the scoring tool has
a great deal of subjectivity. The goal was to reduce the subjectivity with the education module
by providing clear definitions of each of the 21 components of the scoring tool. Following the
completion of the education modules, each of the 58 participants achieved 100%, which means
the education module was effective.
To evaluate our outcome measures, finance pull ICD9 and ICD10 diagnosis codes
associated with NAS and the patient’s LOS. In 2017, there were 23 cases of babies with NAS
who stayed an average of 31 days and were treated for an average of 34 days. After the
implementation of the guideline and the completion of the education modules, the same finance
reports were pulled. In 2019, there were 19 cases who stayed and average of 17 days and were
treated for an average of 20 days. Overall, while the number of NAS cases remains steady, the
interventions had an important impact on the average length of stay and the length of treatment.
Outcome Analysis
While the number of NAS cases remained steady, differences in absolute numbers for
LOS, LOT, and the cost of hospitalization showed a downward trend (Appendix I, Figure I4),
which was an expected finding based on the synthesized body evidence.
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Financial Impact
The organization began considering the NAS patient population in 2014 due to its
exorbitant cost of care. Project implementation occurred in late 2018. Impact outcomes were
evaluated pre-project implementation in 2017, when the hospital had 23 patients with NAS who
stayed an average of 34 days, accumulating a total of $499,709 in hospital charges. In 2018,
during project implementation, there were 28 cases who stayed 13 fewer days than the year
before, resulting in a total cost of $313,799. In 2019, post project implementation, there were 19
cases of NAS who stayed an average of 17 days at a cost of $192,573. The total savings from
2017 to 2019 was $307,136, which supported the findings in the body of evidence (Appendix I,
Figure I5).
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Chapter 5: Project Sustainability Discussion, Conclusions, and Recommendations (EBP
Process Step 5 & 6)
Implications of Project Results
By providing foundational education and implementing a standardized treatment
guideline for the care of infants with NAS, the healthcare team practices consistently resulting in
a reduction in hospitalization and costs. There has been a noted shift in culture within the units
involved in this project. I have seen staff identify external educational material still using old
terminology such as “addicted” in relation to the babies impacted with NAS. Babies are not
“addicted” but rather harbor a physical dependence on the medication they were exposed to.
This same shift in staff and physician perception has also been impacted the relationship
between staff and the mothers of these patients. Through the trauma-informed care education,
the staff now understand the mother’s history and past trauma(s) may contribute to her use of
drugs. Additionally, staff and physicians now know addiction is a medical condition rather than
a choice. Shifting staff perceptions and attitudes towards the mother has led to staff empowering
the mother to take an active and engaged role in her baby’s treatment.
There has been a marked improvement in the relationship between staff, physicians, and
Child Protective Services (CPS) following the implementation of this project’s interventions.
The improved partnership with CPS enabled staff to advocate on behalf of the mother and baby
and develop safety plans with CPS that not only meet case worker expectations but enabled ongoing incorporation of non-pharm interventions into patient’s care by the mother.
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Project Sustainability Plans
Two quarterly reports will be generated: 1) a quarterly report for the number of NAS
cases, the total length of hospital stay, and associated hospital costs will be requested by
appointed NAS Council member(s) and submitted to a finance representative. 2) The finance
report will be shared with the NAS Council pharmacy representative in which they will collect
the total duration of morphine treatment on each NAS case identified in the finance report. To
facilitate this, I added quarterly report appointments to the calendar of each of the NAS Council
members involved in data management. Assigned data collectors will keep a secure spreadsheet
of all data for ongoing monitoring for trends. Discussion of quarterly data will occur at specified
NAS Council meetings and action plans developed to address negative trends. To ensure the
NAS treatment guideline is based on the latest evidence, the guideline will enter the 2-year
policy review cycle, in which the evidence will be explored for any new recommendations to
update the guideline. Quarterly reports and updates to the guideline will be communicated via
daily huddles, email, and weekly newsletters.
Implications of Results to the Community/Organization
While Gracelynn was not able to benefit from this project, other babies like her will
benefit from the consistent evidence-based care at a significantly reduced cost. Dissemination of
this project via poster fairs (Appendix J, Figure J1), podium presentations, and publication will
benefit other healthcare facilities seeking to improve the care they deliver their own patients with
NAS. Through our improved partnership with CPS case workers, we expect CPS caseworkers
will share their experiences with other organizations, highlighting our work as the benchmark for
successful outcomes with the NAS population. One of the most powerful implications of this
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project is the mothers will feel a sense of connection and ownership because we have
incorporated them into the treatment team and educated them on the vital role they play in their
baby’s treatment journey.
Key Lessons Learned
The first key lesson learned through this process is that evidence-based practice is
effective in addressing clinical issues. In this case, as the evidence suggests, the implementation
of a comprehensive treatment guideline for the care of infants with NAS reduced the length of
hospital stay, the duration of morphine/medication treatment, and can save the hospital thousands
of dollars for our organization. Second key lesson is that consistent utilization of the guideline is
key to ongoing success. Toward that end, the sustainability plan will ensure data points are
regularly evaluated and negative trends are investigated using quality improvement process, such
as root cause analysis.
The third key lesson learned is that barriers to success must be anticipated and plans
developed to address those barriers. When faced with unplanned obstacles, it is important to
evaluate all options and make the best decision based on those available options. The options
may not include the perfect solution, but project leaders should move forward, learn from the
situation, and adjust later as the project fully develops. The final key lesson for this project was
the despite best laid plans, unforeseen flaws in the plan are bound to happen, such as the
inadequacies of the educational module platform and inaccessibility to physicians. Key lessons
learned in this project will facilitate better project process and outcome success with the next
one.
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Project Recommendations
The best evidence-based treatment for patients with NAS is consistency in guideline
implementation, which guarantees a standard of care across patients, providers, and time. When
this project began, adherence to the new guideline was varied. Continuing to offer the NAS
educational modules will be of utmost importance – in orientation of new nurses as well as
annual competency blitz. This will ensure that babies are treated appropriately and are
discharged in the appropriate time period.
With the success with NAS patients in our organization, there is the potential for
implementing the new NAS guideline system-wide. One challenge to system-wide
implementation is that two different neonatology groups care for these patients. The practice
approach varies between these two provider groups. The key to system-wide implementation
will be the project leader cultivating relationships with these provider groups, helping them
understand the evidence underpinnings of the guideline, the success of this project and how
appointed NAS Council member can help them implement the guideline in their organization,
including ongoing updates to ensure its evidence-based foundations.
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Chapter 6: DNP Practice-Scholar Role Actualization
Role Impact
I define my leadership style as a combination of transformational, situational, and servant
leadership (Appendix K, Figure K1). During this project, I drew on components of each of these
leadership styles to motivate and stimulate those involved in the project’s development,
implementation, and completion. As a servant leader I ensured staff impacted by this project had
a voice and encouraged their participation, which fostered their professional growth through a
trusting give and take relationship. When issues developed, I called upon my situational
leadership skills and reassessed the situation with my team. We examined participants and their
readiness to receive change. From this, I adjusted my methods to meet their needs and improve
their commitment to the project.
As a DNP clinical expert, my impact on the organization is broad and stretches from
finance, through policy development, patient outcomes, and beyond. I plan to draw on my DNP
program experience to lead my organization to improved healthcare delivery through translation
of the best and most current evidence into practice. I hope to implement this guideline into
practice system wide to each of our entities may delivery high-quality evidence-based care. I
have recently started hosting talks with visiting nursing students about my experience in the DNP
program in hopes of inspiring them to continue their education and contribute to the ongoing
success of the nursing profession.
When evaluating my career trajectory, I plan to continue to increase my engagement
within my organization by taking on additional leadership roles. Should an opportunity to
advance present itself, I am now more confident in my abilities to move to the next level. I will
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continue to push myself beyond my comfort level to foster growth both personally and
professionally. I believe this project has provided an opportunity for others (within the
organization) to see my potential and therefore seek me out for important projects and tasks. I’m
open to any and all opportunities that come my way and I contribute that directly to my
experience in this program.
Summary
Through a keen awareness of my individual strengths and emotional intelligence, as they
have been woven through this program, I have found success. With the regular use of selfreflection, I have focused energy on improving my areas of opportunity, which will benefit my
future career momentum. This program has not only helped me improve as a leader and a DNP
clinical expert but empowered me to seize each opportunity as a monumental event to explore
things I would not normally have tried.
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Appendix A. Systematic Search

Figure A1 Systematic Search Strategy Flowchart
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Appendix B. Critical Appraisal
Table B1: Levels and Type of Evidence
1

2

3

4

5

6

X

X

--

--

--

--

--

--

--

--

--

--

--

--

--

--

--

--

--

--

X

X

X

--

--

--

--

--

--

X

--

--

--

--

--

--

--

--

--

--

--

--

Level I: Systematic review or meta-analysis
Level II: Randomized controlled trials
Level III: Controlled trials without randomization
Level IV: Case-control or cohort study
Level V: Systematic review of qualitative or descriptive studies
Level VI: Qualitative or descriptive study (includes evidence
implementation projects)
Level VII: Expert opinion or consensus

1 = Bagley, et al., (2014); 2 = Edwards, et al., (2016); 3 = McKnight, et al., (2016); 4 = Short, et
al., (2016); 5= Welle-Strand (2013); 6 = Boucher et al., (2017)
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Appendix B. Critical Appraisal & Synthesis
Table B2: Evaluation Table

Conceptual
Framework

Used with permission, © 2007 Fineout-Overholt
CLINICAL QUESTION: In neonates with Neonatal Abstinence Syndrome (P), how does adding non-pharmacologic therapies to the current medication protocol (I) compared to current
medication protocol alone (C) affect the length of stay and length of treatment (O) within one quarter (T)?
Citation: author(s), date
Purpose of
Design/
Major
Data
Appraisal of Worth to
of publication& title
Study
Method
Sample Setting
Variables
Measurement
Analysis
Study Findings
Practice
Studied and
of Major
Strength of the Evidence
Their
Variables
(i.e., level of evidence +
Definitions
quality [study strengths and
weaknesses])
RECOMMENDATIONS
1. Bagley, S. et al. (2014).
Summarize
N/A Design:
IV 1 - BF
DV 1 - LOS
-OR
Nonpharm:
LOE=1
 BF - ↓LOS (mean
Review of the assessment
the evidence
SR
BF: n=452
IV 2 – RI
DV 2 - LOT
-CI
Weaknesses
LOS 14.7 [SD
and management of
of NAS
RI: n=183
IV 3 - Beds
-SD
limited evidence, ↓sample
14.9], ↓ LOT
neonatal abstinence
interventions
Searched:
Bed: n=44,
IV 4 – Position
sizes
(OR=0.36 95% CI
syndrome.
PM, CO, hand
Position: n=48,
IV 5 - NIA
0.18-0.71; p<0.05),
Addiction Science &
search
Strengths
 RI= ↓LOS (mean
Clinical Practice, 9(1), 19.
BF-↑sample size (incl RCT),
LOS 11.8; p<0.05),
Nonpharm:
↑CI, ↓p-value
↓LOT (mean LOT
TY: 879, Y:
5.9; p<0.05)
13
Conclusion
BF, RI, & position ↓LOS,
 Beds: ↓LOT
Pharm:
scores, LOT, req kcal, &
TY: 940, Y: 7
restlessness, ↑sleep & feeding
 Position
(prone)=↓peak &
Recommendations
mean scores;
Beds, BF, & RI
↓mean kcal intake
 NIA - ↑ sleep,
↓restlessness,
↑feeding
2. Edwards, et al., (2016).
Nonpharmacologic
management of Neonatal
Abstinence Syndrome: An
integrative review.

Summarize
evidence of
nonpharm
interventions
for tx of NAS

N/A

Design:
SR
Searched: CL,
PM, ML, & PI

BF: n= 6 trials
(n=565 AG)
Position: n=1
trial
(n=48)

IV 1 - BF
IV 2 - Position
IV 3 - RI
IV 4 Acupun/Acupre

DV 1 - LOS
DV 2 - LOT

-CI
-RR

 BF: ↓LOS & LOT
 Position: Prone
=↓severity of NAS
 RI: ↓LOT (-12.7

LOE=1
Weaknesses
Overall - ↓ability to
generalize findings, ↓sample
size, ↓subjects of varying

42
Legend: Adm-Admission, AG-Aggregate, Asmt-Assessment, BF-Breastfeeding, Bupren-Buprenorphine, CF – Conceptual Framework, CI-Confidence Interval, CL, CINAHL, Clin-Clinical, CO-Cochrane
Database, DTO-Diluted, Tincture Opium, DV-Dependent Variable, EB – Embase Database, Eval-Evaluate, Exp-Experimental, Finnegan-Neonatal Narcotic Abstinence Scoring System, F/U-Follow Up,
IB-Infant Behaviors, ICC- Intraclass correlation coefficient, IM-Infant Massage, IRR-Inter-rater reliability, IQR-Interquartile Range, IV-Independent Variable, KC-Kangaroo Care, Kcal-Kilocalories,
Lipsitz-Neonatal Withdrawal Inventory, LOS-Length of Stay, LOT-Length of Treatment, MA-Meta Analysis, MD-Mean Difference, MIR, Maternal Infant Relationship, Med Req-Medication Required,
Mgt-Management, ML – Medline, Modified Finnegan-MOTHER NAS Scale, MSO4-Morphine, NAS-Neonatal Abstinence Syndrome, N/D – Not Determined, NIA-Non-insertion Acupuncture, NNWINeonatal Narcotic Withdrawal Index, Nonpharm-Nonpharmacologic treatment, NOS-Neonatal Opium Solution, NWI-Neonatal Withdrawal Inventory, OR-Odds Ratio, Pharm-Pharmacologic treatment,
Phenobarb-Phenobarbitone, PI – PsychInfo, PM-PubMed, Position-Positioning (Prone vs. Supine), PT-Patient, RCT-Randomized Controlled Trial, RD-Risk Difference, Rec’d- Received, RI-Rooming-in,
RR-Risk Ration, RX-Treatment, SC-Supportive Care, SD-Standard Deviation, Sen/Spec-Sensitivity/Specificity, SX-Symptoms, SZ-Seizures, TO-Tincture of Opium, TX-Treatment, TY-Total Yield,
WKS-Weeks, WMD-Weighted Mean Difference.

Purpose of
Study

Conceptual
Framework

Citation: author(s), date
of publication& title

Neonatal Network,
35(5), 305-313.

3. McKnight et al., (2015)
Rooming-in for infants at
risk of Neonatal
Abstinence Syndrome.
American Journal of
Perinatology, 33(05), 495501.

Design/
Method

TY: 112, Y:
14

Examine RI
program for
infants with
NAS

N/A

Design:
CC/Cohort
Single-center,
retro cohort

Sample Setting

RI: n=3 studies
(n=1353 AG)
Acupun
Acupre: n=2
studies
(n=130 AG)
Bed: n=2 studies
(n=44 AG)

n=44

Major
Variables
Studied and
Their
Definitions

Measurement
of Major
Variables

Data
Analysis

IV 5 - Bed

days. p<0.003),
↓LOS (-11.7 days,
p<0.001)
Acupun/Acupre:
↑sleep & feeding,
↓agitation; potential
for TX - not stat sig
Bed: ↑sensitivity
with rocking beds not effective;
↓incidence of NAS
w/ waterbed, ↓LOT

IV 1 – RI

DV 1 – LOS
DV 2 – LOT

-IQR
-p-value

Infants born
between 2012
and 2014, ≥36
wks w/ NAS

Evaluate the
relationship
between BF
and LOS in

N/A

Design:
CC/Cohort

n=3,725

 ↓LOS: NICU
(IQR 24, 3-56;
24) vs RI (IQR 5,
3-34; 3) (p<0.001)
 No stat sig: LOT
1st line med:
NICU (IQR 29.5,
8-73; 23 vs RI
(IQR 24, 23-29,
IQR not
calculated)
(p=0.83)

2 groups:
RI (n=24)
RI: (n=20)

4. Short et al., (2016).
The association between
breastfeeding and length
of hospital stay among

Study Findings

IV 1 – BF

DV 1 - LOS

-IQR
-p-value

 ↓LOS in BF
babies – median
LOS 10 days

Appraisal of Worth to
Practice
Strength of the Evidence
(i.e., level of evidence +
quality [study strengths and
weaknesses])
RECOMMENDATIONS
cultures, ethnicities,
socioeconomic status
Strengths
-13/14 studies found
nonpharm has positive effect
RI findings stat sig
BF findings stat sig
Conclusion
BF, RI, Position found
supportive TX for NAS
Recommendations
BF, RI, and position
LOE=4
Weaknesses
Small sample size ↓ ability to
test BF hypothesis
Non-randomization
uncontrolled design
Drugs of exposure not
compared
Strengths
Stat sig results for LOS
Conclusion
RI may be supportive for SX
mgt Recommendations
RI
LOE=4
Weaknesses
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Legend: Adm-Admission, AG-Aggregate, Asmt-Assessment, BF-Breastfeeding, Bupren-Buprenorphine, CF – Conceptual Framework, CI-Confidence Interval, CL, CINAHL, Clin-Clinical, CO-Cochrane
Database, DTO-Diluted, Tincture Opium, DV-Dependent Variable, EB – Embase Database, Eval-Evaluate, Exp-Experimental, Finnegan-Neonatal Narcotic Abstinence Scoring System, F/U-Follow Up,
IB-Infant Behaviors, ICC- Intraclass correlation coefficient, IM-Infant Massage, IRR-Inter-rater reliability, IQR-Interquartile Range, IV-Independent Variable, KC-Kangaroo Care, Kcal-Kilocalories,
Lipsitz-Neonatal Withdrawal Inventory, LOS-Length of Stay, LOT-Length of Treatment, MA-Meta Analysis, MD-Mean Difference, MIR, Maternal Infant Relationship, Med Req-Medication Required,
Mgt-Management, ML – Medline, Modified Finnegan-MOTHER NAS Scale, MSO4-Morphine, NAS-Neonatal Abstinence Syndrome, N/D – Not Determined, NIA-Non-insertion Acupuncture, NNWINeonatal Narcotic Withdrawal Index, Nonpharm-Nonpharmacologic treatment, NOS-Neonatal Opium Solution, NWI-Neonatal Withdrawal Inventory, OR-Odds Ratio, Pharm-Pharmacologic treatment,
Phenobarb-Phenobarbitone, PI – PsychInfo, PM-PubMed, Position-Positioning (Prone vs. Supine), PT-Patient, RCT-Randomized Controlled Trial, RD-Risk Difference, Rec’d- Received, RI-Rooming-in,
RR-Risk Ration, RX-Treatment, SC-Supportive Care, SD-Standard Deviation, Sen/Spec-Sensitivity/Specificity, SX-Symptoms, SZ-Seizures, TO-Tincture of Opium, TX-Treatment, TY-Total Yield,
WKS-Weeks, WMD-Weighted Mean Difference.

infants diagnosed with
Neonatal Abstinence
Syndrome: A populationbased study of in-hospital
births.
Breastfeeding Medicine,
11(7), 343-349

Purpose of
Study

Conceptual
Framework

Citation: author(s), date
of publication& title

infants w/
NAS.

Design/
Method

Pennsylvaniaretro cohort
Retrospective
chart review

Sample Setting

Major
Variables
Studied and
Their
Definitions

Measurement
of Major
Variables

Data
Analysis

Hospital d/c data
used to collect
subjects born
between 2012
and 2014 w/
NAS using ICD9

Study Findings

(IQR 5-19)
 Stat sig inverse
relationship
between BF and
LOS (p=0.008)
(Adjusted p=0.05)
Adjusted LOS
↓9.4%

5. Welle-Strand, et al.,
(2013). Breastfeeding
reduces the need for
withdrawal treatment in
opioid-exposed
infants. Acta Paediatrica,
n/a-n/a.

Examine BF
impact on
incidence and
duration of
NAS TX.

N/A

Design:
Cohort

(n=139 women;
n=161 babies)

Part I:
retrospective
questionnaire
Part II:
prospective
data collection
Part III:
retrospective
phone
interview

Part I: (n=36)
Part II: (n=36)
Part III:(n=52)

IV 1: BF

DV 1: LOT

-p-value

↓LOS (p=0.02) in
BF babies whose
mother is receiving
MMT

Appraisal of Worth to
Practice
Strength of the Evidence
(i.e., level of evidence +
quality [study strengths and
weaknesses])
RECOMMENDATIONS
Using ICD-9 has been
problematic in the past due to
potential incorrect coding
Limited info on maternal
drugs used
Limited info on maternal TX
Illicit vs RX?
Limited data on BF practices
(initiation, duration,
continuation etc)
Strengths
Large sample size
Stat sig results
Adjusted results stat sig
Conclusion
BF beneficial to infants
w/NAS
Recommendations
BF
LOE=4
Weaknesses
Retrospective design
(incomplete data)
Varied experience with
assessment of NAS
Limitations of questionnaire
Small subject size
Strengths
National study
Compared mothers in both
MMT and BMT treatment
plans
Study population = subjects
on OMT >1 year
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Legend: Adm-Admission, AG-Aggregate, Asmt-Assessment, BF-Breastfeeding, Bupren-Buprenorphine, CF – Conceptual Framework, CI-Confidence Interval, CL, CINAHL, Clin-Clinical, CO-Cochrane
Database, DTO-Diluted, Tincture Opium, DV-Dependent Variable, EB – Embase Database, Eval-Evaluate, Exp-Experimental, Finnegan-Neonatal Narcotic Abstinence Scoring System, F/U-Follow Up,
IB-Infant Behaviors, ICC- Intraclass correlation coefficient, IM-Infant Massage, IRR-Inter-rater reliability, IQR-Interquartile Range, IV-Independent Variable, KC-Kangaroo Care, Kcal-Kilocalories,
Lipsitz-Neonatal Withdrawal Inventory, LOS-Length of Stay, LOT-Length of Treatment, MA-Meta Analysis, MD-Mean Difference, MIR, Maternal Infant Relationship, Med Req-Medication Required,
Mgt-Management, ML – Medline, Modified Finnegan-MOTHER NAS Scale, MSO4-Morphine, NAS-Neonatal Abstinence Syndrome, N/D – Not Determined, NIA-Non-insertion Acupuncture, NNWINeonatal Narcotic Withdrawal Index, Nonpharm-Nonpharmacologic treatment, NOS-Neonatal Opium Solution, NWI-Neonatal Withdrawal Inventory, OR-Odds Ratio, Pharm-Pharmacologic treatment,
Phenobarb-Phenobarbitone, PI – PsychInfo, PM-PubMed, Position-Positioning (Prone vs. Supine), PT-Patient, RCT-Randomized Controlled Trial, RD-Risk Difference, Rec’d- Received, RI-Rooming-in,
RR-Risk Ration, RX-Treatment, SC-Supportive Care, SD-Standard Deviation, Sen/Spec-Sensitivity/Specificity, SX-Symptoms, SZ-Seizures, TO-Tincture of Opium, TX-Treatment, TY-Total Yield,
WKS-Weeks, WMD-Weighted Mean Difference.

Purpose of
Study

6. Boucher, A. (2017).
Nonopioid management of
neonatal abstinence
syndrome. Advances in
Neonatal Care, 17(2), 8490.

Review the
efficacy of RI
and
Acupuncture
on LOS

Conceptual
Framework

Citation: author(s), date
of publication& title

N/A

Design/
Method

Design:
Level V MetaSynthesis
Searched:
PM, ML, CL,
& EB

Sample Setting

n=8 studies
RI:
n=5 studies
(n=122)

Major
Variables
Studied and
Their
Definitions

IV 1: RI
IV 2:
Acupuncture

Measurement
of Major
Variables

DV 1: LOS

Data
Analysis

--

Study Findings

RI: ↓LOS
Acupuncture:
inconclusive

Appraisal of Worth to
Practice
Strength of the Evidence
(i.e., level of evidence +
quality [study strengths and
weaknesses])
RECOMMENDATIONS
High proportion of BF
women
Conclusion
BF beneficial to ↓LOS in
babies born to mothers on
MMT
Recommendations
BF
LOE=5
Weaknesses
Small study size (sample
methods not indicated)
Strengths
RI stat sig ↓LOS
RCTs included in analysis

Acupuncture:
n=158 (n=3)

Conclusion
RI supportive to symptom
management and can ↓LOS
Recommendations
RI
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Legend: Adm-Admission, AG-Aggregate, Asmt-Assessment, BF-Breastfeeding, Bupren-Buprenorphine, CF – Conceptual Framework, CI-Confidence Interval, CL, CINAHL, Clin-Clinical, CO-Cochrane
Database, DTO-Diluted, Tincture Opium, DV-Dependent Variable, EB – Embase Database, Eval-Evaluate, Exp-Experimental, Finnegan-Neonatal Narcotic Abstinence Scoring System, F/U-Follow Up,
IB-Infant Behaviors, ICC- Intraclass correlation coefficient, IM-Infant Massage, IRR-Inter-rater reliability, IQR-Interquartile Range, IV-Independent Variable, KC-Kangaroo Care, Kcal-Kilocalories,
Lipsitz-Neonatal Withdrawal Inventory, LOS-Length of Stay, LOT-Length of Treatment, MA-Meta Analysis, MD-Mean Difference, MIR, Maternal Infant Relationship, Med Req-Medication Required,
Mgt-Management, ML – Medline, Modified Finnegan-MOTHER NAS Scale, MSO4-Morphine, NAS-Neonatal Abstinence Syndrome, N/D – Not Determined, NIA-Non-insertion Acupuncture, NNWINeonatal Narcotic Withdrawal Index, Nonpharm-Nonpharmacologic treatment, NOS-Neonatal Opium Solution, NWI-Neonatal Withdrawal Inventory, OR-Odds Ratio, Pharm-Pharmacologic treatment,
Phenobarb-Phenobarbitone, PI – PsychInfo, PM-PubMed, Position-Positioning (Prone vs. Supine), PT-Patient, RCT-Randomized Controlled Trial, RD-Risk Difference, Rec’d- Received, RI-Rooming-in,
RR-Risk Ration, RX-Treatment, SC-Supportive Care, SD-Standard Deviation, Sen/Spec-Sensitivity/Specificity, SX-Symptoms, SZ-Seizures, TO-Tincture of Opium, TX-Treatment, TY-Total Yield,
WKS-Weeks, WMD-Weighted Mean Difference.

Appendix B. Critical Appraisal & Synthesis
Table B3: Nonpharmacologic Interventions and Impact on LOS/LOT

1
2
3
4
5
6

Synthesis

Breastfeeding

Rooming-in

Beds

Position

LOS↓*

LOS↓*
LOT↓*
LOS↓
LOT↓
LOS ↓
LOT n/m
--

LOS n/m
LOT↓
LOS↓
LOT n/m
--

LOS n/m
LOT n/m
LOS n/m
LOT n/m
--

Acupuncture
Acupressure
LOS n/m
LOT n/m
LOS n/m
LOT n/m
--

--

--

--

--

--

--

--

--

--

LOS↓
LOT↓
-LOS ↓
LOT n/m
LOS n/m
LOT↓*
-3 of 3 reduced
LOS
2 of 2 reduced
LOT

LOS↓*
LOT n/m
4 of 4 reduced
LOS
2 of 2 reduced
LOT

1 of 2 reduced
LOS
1 of 2 reduced
LOT

None evaluated

LOS incon
LOT n/m
1 incon

46
1 = Bagley, et al., (2014); 2 = Edwards, et al., (2016); 3 = McKnight, et al., (2016); 4 = Short, et al., (2016); 5= Welle-Strand
(2013); 6 = Boucher et al., (2017)
LOS – length of stay, LOT – length of treatment, n/m – not measured, ↓ - decreased, * - statistical significance, incon inconclusive

Appendix B. Critical Appraisal & Synthesis
Table B4: Systematic Review by Bagley et al.
LOS

LOT

Abdel-Latif (2006)

BF = ↓*

n/m

Dryden (2009)

n/m

n/m

McQueen (2011)

n/m

n/m

Pritham (2012)

BF = ↓

n/m

O-Connor (2013)

n/m

n/m

Wachman (2013)

BF = ↓*

n/m

Welle-Strand (2013)

n/m

BF = ↓*

Hunseler (2013)

RI = ↓

RI = ↓

Abrahams (2007)

RI = ↓*

RI = ↓*

D’Apolito (1999)

n/m

n/m

Oro (1988)

Bed = ↓

n/m

Maichuk (1999)

n/m

n/m

Filippelli (2012)

n/m

n/m

Recommendation

BF & RI reduce LOS

RI reduce LOT

47
LOS – length of stay, LOT – length of treatment, n/m – not measured, ↓ - decreased, * statistical significance, RI – Rooming-in, BF - Breastfeeding

Appendix B. Critical Appraisal & Synthesis
Table B5: Systematic Review of Non-Pharmacological Interventions by Edwards et al.
LOS

LOT

Addel-Latif et al. (2006)

n/d

n/d

Abrahams et al. (2007)

RI↓*

RI↓*

Abrahams et al. (2010)

RI↓*

n/d

Ballard (2002)

BF↓

BF↓

D’Apolito (1999)

n/d

n/d

Filippelli et al. (2012)

n/d

n/d

Hodgson & Abrahams (2012)

n/d

n/d

Isemann et al. (2011)

BF↓

BF↓

Maichuk et al (1999)

n/d

n/d

McQueen et al. (2011)

n/d

n/d

O’Connor et al. (2013)

n/d

n/d

Oro & Dixon (1988)

n/d

n/d

Schwartz et al (2011)

n/d

n/d

Welle-Strand et al. (2013)

n/d

BF↓

Recommendation

BF & RI reduced LOS

BF reduced LOT

LOS – length of stay, LOT – length of treatment, n/m – not measured, ↓ - decreased, * statistical significance, RI – Rooming-in, BF - Breastfeeding

Appendix C. EBP and Change Models

Figure C1 Johns Hopkins Nursing Evidence-Based Practice Model (JHMEBP)

Appendix C. EBP and Change Models

Figure C2 Lewin's Change Model

Appendix D. Executive Summary
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Appendix E. Letters of Support & Agreement
Form E 1 Letter of Support CNO
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Appendix E. Letters of Support & Agreement
Form E 2 Industry Mentor Agreement – Chan
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Appendix E. Letters of Support & Agreement
Form E2: Industry Mentor Agreement – Chan Page 2
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Appendix E. Letters of Support & Agreement
Form E 3 Industry Mentor Agreement - Kakkilaya
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Appendix F. Ethics Review
Ethics Review Form F1 Faculty Attestation of Compliance with the UTT DNP EPIP Ethics Form
I attest that I have reviewed the UTTYLER DNP EPIP ETHICS FORM that the DNP student has
completed based on justification using the UTTYLER DNP PROGRAM IRB DISCERNMENT FORM.
I agree that the need for ethics review determination is correct and this DNP EPIP requires:

X FM Review Only
 -HIPAA ethics review by DNP Ethics Board
 HIPAA review form completed
 Organizational IRB review (based on policies of the organization in which the EPIP will
be implemented)

_Ellen Fineout-Overholt__

_11-10-18_

Faculty Mentor Signature

Date
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Appendix F. Ethics Review
Ethics Review Form F 2 QIEBP Worksheet
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Appendix F: Ethics Reviews

59

Appendix F. Ethics Review
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Appendix F. Ethics Review
Ethics Review Form F 3 Texas Health Resources IRB Approval Letter
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Appendix G. Implementation Plan
Table G1: Logic Model
Program Name: Adding Non-Pharmacological Interventions to a Morphine Protocol to Improve the Treatment of Infants
with Neonatal Abstinence Syndrome: An Evidence-Based Innovation Project
Program Goal: Improve the care and treatment of infants with NAS thereby reducing the treatment time and length of
hospital stay
Resources/Inputs: (What resources are needed for the project to be successful… The human, financial, organizational, and
community resources available to do the work.)
Necessities List
Associated Costs
Wish List
 12 - Neonatologists
 12 – Neonatologists: UTSW
 Support from all healthcare
Salaried MDs
providers
 156 - Staff RN (FCC, SCN,
NICU)
 65 - Staff RN (FCC, SCN,
 Positive attitude and graceful
NICU): 45/hr
adaptation from healthcare
 5 - Nurse leaders (FCC, SCN,
providers toward protocol
NICU)
 5 - Nurse leaders (FCC, SCN,
changes
NICU): $60/hr
 3 - OT/PT
Human

Support from senior leaders and
 3 - OT/PT: $35/hr
Resources
 15 - PCTs
administrators
 15 – PCTs: $14/hr
 10 - Administrators
 10 – Administrators: $80/hr
 10 - Senior leaders
 10 - Senior leaders: $75/hr
 12 NAS committee members for
policy creation, review, and
 12 NAS committee members:
finalization
$45/hr
 Laptop
 Budget Neutral
 Already own these items
Office
Supplies
 Projector
 Budget Neutral
 Access to patient
 Access to pt. information: No
 None
charts/information
charge
Organization  Access to NAS protocols,
 Access to NAS protocols,
Resources
policies, and/or procedures
policies, and/or procedures: No
charge
 Staff breakroom for educational
training
 Staff breakroom: No charge
63

Resources/Inputs: (What resources are needed for the project to be successful… The human, financial, organizational, and
community resources available to do the work.)
Necessities List
Associated Costs
Wish List
 Food and drinks for each

educational session
All items are budget neutral as they
are included in the cost of
 Breastmilk refrigerators
admission:
 Breastmilk freezers
 Breastmilk refrigerators: $147 x
 Breastmilk pumps
34
 Disposable breast pump kits

Breastmilk freezers: $350 x 2
 Bottles
 Breastmilk pumps: $150 x 34
 Nipples
 Disposable breast pump kits:
 Breast pump supply cleaning
$25/each
kits
 Bottles: $0.10/each
o Palmolive dish soap
 Nipples: $0.06/each
o Large pink basin
o Bottle brush
 Breast pump supply cleaning kit:
$1.50/each
OUTPUTS
Activities
Audience(s)
(What do project staff
(What population
needs
to be engaged?)
need to do?)
Review current NAS
Active stakeholders
treatment protocol.
Revise protocol based
on conclusive
evidentiary support
from systematic
search to include nonpharm interventions:
BF & RI

OUTCOMES
Short-Term
(At launch)
Protocol will be
finalized & approved
by medical director
then placed as active
in Policy Connect for
launch
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Mid-Term
(1-month)

Long-Term
(3-months)

OUTPUTS
Activities
(What do project staff
need to do?)
Educate passive
stakeholders
regarding updated
NAS treatment
protocol and
implications to
practice
Chart reviews

Audience(s)
(What population
needs to be engaged?)
Passive stakeholders
required include:
Neo MDs, Staff RNs
in SCN, NICU, &
FCC, PS, & NS:

Ongoing data
collection

Cyndi & Catrina

OUTCOMES
Short-Term
(At launch)

Mid-Term
(1-month)

100% passive
stakeholders received
education by launch
date

100% infants admitted
with dx of NAS will
receive treatments as
outlined in new protocol

Reduced LOS and
LOT

100% of admitted
infants with NAS will
have chart reviews
evaluating stakeholder
compliance with new
protocol
100% of patients with
NAS will have data
extracted and retained
for review following
project completion.
Preliminary data
comparison of pre and
post data will be
conducted to determine
efficacy of new protocol

100% staff compliance
with updated protocol

Cyndi & Catrina

Long-Term
(3-months)

100% of patients with
NAS will have data
extracted and retained
for review following
project completion.
Final data comparison
will be completed and
reviewed.

External Influencing Factors
Environment/Setting 55555
Other Programs
Parkland: NAS Project Development and Mommies Program (Dr. Venkat Kakkilaya)
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Influences





Dr. Venkat Kakkilaya (NAS project MD champion); Dr. Christina Chan (Neonatal Medical Director
at THD)

Assumptions
Staff believe mothers who use drugs do not care about their babies and do not want to stay with their baby in the
hospital
Staff believe that it doesn’t matter if the mother rooms in or not, the baby is best treated with pharmacological
interventions
Staff believe all mothers with a history of drug use (but not currently using) should now be allowed to breastfeed
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Appendix G. Implementation Plan

Figure G1 Gantt Chart
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Appendix G. Implementation Plan
Table G2: Timeline for an EBP Change Project
PICOT Question: PICOT Question: In neonates with Neonatal Abstinence Syndrome (P), how does adding non-pharmacologic therapies to the
current medication protocol (I) compared to current medication protocol alone (C) affect the length of stay (O) and length of treatment (O)within one
quarter (T)?
Team Leader: Cyndi Kelley
Team Members: Catrina Mazzella, Beverly McMeans, Veronica Salvador, Suzanna Ice, Cecilia Amar, Racheal Daniel, Kellie Classen, Elaine Simon,
Annie Ivy, Candace Haney, Yunlin Huang, Nuala Murphy, Sonya Manibusan, Stephanie Schaefer, Kimberly Williams.
Agency Contact/Mentor Contact Info: Dr. Christina Chan (ChristinaChan@UTSouthwestern.edu and Dr. Venkat Kakkilaya
(VenkatKakkilaya@UTSouthwestern.edu
Preliminary
o Select the EBP model
Notes: John Hopkins
OUTCOMES: Reduce the
JHNEBP EBP Model
Checkpoint
o Select the change model
Nursing Evidence-Based
length of stay and length of
A
o How it will they guide the
Practice Model
treatment in infants with
implementation project
This model was selected due NAS.
to the problem-solving
approach to clinical
Lewin’s Change Model
decision-making. This
model is a three-step
process: 1. Practice question,
2. Best evidence, 3.
Translation into practice

Preliminary
Checkpoint
B

o

o
o

Who are the stakeholders for your
project?
o Active (on the implementation
team) & supportive (not on the
team, but essential to success)
Identify project team roles &
leadership
Begin acquisition of any necessary
approvals for project implementation

Lewin’s Change Theory is
the basis for this change
model and breaks down the
process of change into three
steps, Unfreeze, Change, and
Freeze.
Active stakeholders:
Cyndi Kelley, Catrina
Mazzella, Beverly
McMeans, Veronica
Salvador, Suzanna Ice,
Cecilia Amar, Racheal
Daniel, Kellie Classen,
Elaine Simon, Annie Ivy,
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All stakeholders aware of
project
Roles within project have
been emailed
Buy-in has been secured and
letter of approval from CNO
has been received.
Met with nurse scientist.
Must run project through

Stakeholder Power Grid

Kelley DNP EPIP
Stakeholder-Register_PowerInterest Grid 11 16 18.

o

and dissemination (e.g., system
leadership, unit leadership, ethics
board [IRB])
Consult with Agency Contact/Mentor

Candace Haney, Yunlin
Huang
Passive stakeholders
Neonatologists, Staff RNs,
Mother, Infant, CPS
Faculty mentor: Dr. Ellen
Fineout-Overholt
Project Sponsors: Dr. Cole
Edmonson, Suzanne Murphy
Nurse Scientist: Dr. June
Marshall
Roles include:
o Neonatologists: Use
protocol to guide
treatment of infant
o Staff RN: Carry out
actions of protocol as
directed by Neonatologist
o Mother – Received
education from Staff RNs
on role of rooming in and
breastfeeding
o Baby – received treatment
as mandated by protocol
o Faculty and Industry
mentors – provide input
and guidance during all
project phases
o Active stakeholders will
carry out actions of project
through each phase
including education,
implementation, data
collection, and evaluation.
o Passive stake holders will
administer or receive
treatment based on update
protocol
o Project sponsors will serve
as mentors, support
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IRB. Forms must be
completed (Dr. Marshall
altered the documents to
remove research-based
language to better support
evidence-based
implementation project)

measures to obtain any
necessary approvals
(financial, organizational)
o CPS – provides social
service interventions. As
assigned to each case, CPS
worker should receive
education on protocol by
staff RN to be considered
when creating safety plan
for mother/baby dyad.

Checkpoint
One

o
o
o

Checkpoint
Two

o
o
o
o

Hone PICOT question & assure team
is prepared
Build EBP knowledge & skills
Consult with Agency
Contact/Mentor

Conduct systematic search for
evidence & retain studies that meet
criteria for inclusion
Connect with librarian
Meet with implementation group TEAM BUILD
Consult with Agency
Contact/Mentor

Approvals needed/date
obtained/posted on BB
HIPAA regs met?
PICOT Question:
In neonates with Neonatal
Abstinence Syndrome (P),
how does adding nonpharmacologic therapies to
the current medication
protocol (I) compared to
current medication protocol
alone (C) affect the length of
stay (O) and length of
treatment (O)within one
quarter (T)?
Search Results Synopsis

Stakeholders have been
notified via presentation
including PICOT at
leadership meeting.

Stakeholders readily see
how PICOT question drove
systematic search
Search results (see notes
column)
Met with medical librarian
at THD and librarian at UTT
Team meetings to discuss
project status and systematic
search.
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Systematic Search:
Evaluation Table:

Checkpoint
Three

o
o
o
o

Checkpoint
Four

o
o

o
o
o

Critically appraise literature
(including evaluation, synthesis &
recommendation)
Meet with group to discuss how
completely evidence answers question
and drives the project plan;
If needed pose follow-up questions
and re-review the literature as
necessary
Consult with Agency
Contact/Mentor

Recommendation from
Evidence: Synthesis tables
lead to the addition of
breastfeeding and rooming
in as supportive measures in
the treatment of infants with
NAS (BF evidence #1, 2, 4,
&5
RI evidence #1, 2, 3, & 6)

Meet with group
Summarize evidence with focus on
implications for practice & conduct
interviews with content experts as
necessary to benchmark
Begin formulating detailed plan for
implementation of evidence
Include who must know about the
project, when they will know, how
they will know
Consult with Agency
Contact/Mentor

YOUR PLAN FOR
IMPLEMENTATION:
Provide Protocol Specifics,
Dates & Progress Outcomes:

Team met to discuss
evidence conclusions.
Discussed with agency
mentors and all in
agreement BR and RI added
as non-pharm interventions
to current protocol should be
included.
Costs associated with
adding non-pharm
interventions to the
protocol: Time/Salary for
education

Synthesis tables:

Updated NAS Protocol:
Education Modules:

1 NAS Education
Modules - Background and Significance.pptx

2 NAS Education
Modules - Trauma Informed Care.pptx

3 NAS Education
Modules - Addiction.pptx

4 NAS Education
Modules - Finnegan Scoring.pptx

5 NAS Education
Modules - Pharm and Non-Pharm.pptx
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6 NAS Education
Modules - NAS Treatment Guideline.pptx

Checkpoint
Five

o
o

o
o
o
o
o

o
Checkpoint
Six (about
mid-way)

o
o
o
o
o
o
o

Define project purpose- connect the
evidence & the project
Define baseline data collection
source(s) (e.g., existing dataset,
electronic health record), methods, &
measures
Define post project outcome
indicators of a successful project
(process & completion)
Gather valid & reliable outcome
measures
Write data collection protocol
Write the project protocol (data
collection fits in this document)
Finalize any necessary approvals for
project implementation &
dissemination (e.g., system
leadership, unit leadership, IRB)
Consult with Agency
Contact/Mentor
Meet with implementation group
Discuss known barriers & facilitators
of project
Discuss strategies for minimizing
barriers & maximizing facilitators
Finalize protocol for implementation
of evidence, include timeline
Identify resources (human, fiscal, &
other) necessary to complete project
Supply Agency Mentor (& Faculty)
with written IRB approval &
managerial support
Begin work method of dissemination
of initiation of project & progress to

LAUNCH PLAN FOR
IMPLEMENTATION:
Provide what is to happen
when you launch, when and
how do you know it is
successful (i.e., protocol
specific, dates & progress
outcomes):

Baseline data will be
collected using details from
2017 through current
(demographic information,
maternal history, drugs of
exposure, treatment history,
onset of symptoms, all
Finnegan scores,
escalation/weaning, LOS,
and LOT)
Collect financial data and
review with industry
mentors
Present to stakeholders and
begin meetings with
committee for education
planning and
implementation roll out time
period.

Logic model:

 Identify project barriers
 Identify project
facilitators
 Review your timeline –
dates, measures, plans.
 Communicate with key
stakeholders about the
plan – be creative –
maybe a newsletter, flyer,
-- yes, email will do, but
will it be memorable?
 Is your data collection
plan complete?

Data collection plan
complete.
Schedule meetings to
develop treatment guideline.
Gather group and review
other facility’s guidelines to
help shape the document.
Initial drafts should be
reviewed, and input sought
by industry mentor.

Timeline:
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o

Checkpoint
Seven

o
o
o
o
o
o

Checkpoint
Eight

o
o
o
o
o
o

Checkpoint
Nine

o

o
o

date to educate stakeholders about
project – get help from support staff
Include specific plan for how
evaluation will take place: who, what,
when, where & how and
communication mechanisms to
stakeholders
Consult with Agency Contact/Mentor
Meet with implementation group to
review proposed stakeholder
dissemination
Make final adjustment to
dissemination plan with support staff
Inform stakeholders of start date of
implementation
Address any concerns or questions of
stakeholders (active & supportive )
Consult with Agency
Contact/Mentor
LAUNCH EBP implementation
project
Follow project protocol rigorously
Collect Baseline Data
Deliver Evidence-based Intervention
Record process outcomes & lessons
learned
Consult with Agency
Contact/Mentor
Mid-project: Schedule meeting with
all key stakeholders to review
progress outcomes and lessons
learned (and associated adjustments
to protocol) to date.
Don’t forget to include any issues,
successes, aha’s, & triumphs of
project to date.
Consult with Agency
Contact/Mentor

Review pertinent protocol
specifics, dates & progress
outcomes
:

Collect data on progress
outcomes to date and
include in report

Progress Outcomes – are
things working as you
thought they would – why or
why not (reflection)

Keep a journal of lessons
learned and your responses
to them

Progress Outcomes – are
things working as you
thought they would – why or
why not (reflection)

Collect data on further
progress outcomes to date
and include in report
Journal lessons learned and
response.
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Checkpoint
Ten

o
o
o
o

Checkpoint
Eleven

o

o

Complete final data collection for
project evaluation
Analyze baseline compared to final
data; create graphics for distribution
of results
Present project progress and
completion results via poster
presentation to stakeholders
Consult with Agency Contact/Mentor
& Agency Leadership
Review project success, including
progress & completion outcomes,
lessons learned, and any new
questions generated from process
Consult with Agency Contact/Mentor
& consider new questions

Completion Outcomes data
collection.
Analyze the baseline to
completion data change?
Did your implementation
work?
Evaluate progress outcomes
-report on success of project
implementation process

Completion outcomes
(analyze pre/post)
Process outcomes (did
project process go well/not)

Provide Final Evaluation
Report to Faculty & Agency
contact, including Next
Steps for sustainability:

 Dissemination includes
making sure that everyone
is aware of the
implementation process
successes, completion
outcomes and any caveats
(lessons learned) along
the way.
 Dissemination includes
beyond the organization
(poster)
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Project Summary
Poster

Appendix H. NAS Guideline
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Appendix H. NAS Guideline
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Appendix I. Results
Table I6: Education Module Completion Summary by Role
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Appendix I. Results

Figure I 1 Pre/Post Education Results by Title
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Appendix I. Results

Figure I 2 Project Outcome Measure Results by Year – # Cases, ALOS, ALOT
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Appendix I. Results

Figure I 3 Project Outcome Measure by Year – Total Hospital Costs
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Appendix J. Project Poster

Figure J1 Project Poster
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Appendix K. Leadership Model

Figure K1 Leadership Model
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Biosketch
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